Answers are grounded in this paper and cite their sources.
Research uncovers a novel nucleoside-ATTEC compound that inhibits HIV replication in human cells, suggesting a new therapeutic avenue.
HIV-1 reverse transcriptase (RT) has been a key target for HIV treatment, and several RT inhibitors have been utilized in the clinic. However, RT inhibitors are incapable of eradicating reverse-transcribed DNA, and drug resistance has greatly compromised drug efficacy. Here, we have presented a nucleoside-autophagosome-tethering compound (ATTEC) aiming to inhibit HIV by inducing viral cDNA degradation during replication. 5,7-Dihydroxy-4-phenylcoumarin (DP) derivatives with varied linker lengths were designed and synthesized as LC3-binding ligands and further conjugated with 3'-azidothymidine (AZT) via a bioorthogonal click reaction to form nucleoside-ATTECs. After comparing and optimizing the linker length, our developed nucleoside-ATTEC can effectively inhibit HIV replication and infection in human cells without interfering with cell proliferation. Moreover, DP-AZT has been shown to have the capacity for the prolonged inhibition of HIV-1 replication. Therefore, this work provides a good example of developing a nucleoside-ATTEC approach to inhibit HIV replication and infection.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: